证券代码：603123 证券简称：翠微股份 公告编号：临2026-002 债券代码：188895 债券简称：21翠微01 北京翠微大厦股份有限公司 关于控股股东向公司全资子公司提供借款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、借款事项概述 （一）基本情况 翠微集团为公司控股股东，上述事项构成关联交易。根据《上海证券交易所股票上市规则》（2025年4 月修订）第 6.3.18 条规定，关联人向上市公司提供资金，利率水平不高于贷款市场报价利率，且上市公 司无需提供担保，上市公司可以免于按照关联交易的方式审议和披露。根据《公司章程》规定，本次事 项需提交董事会审议，无需提交股东会审议。 （三）董事会审议情况 2026年2月9日，公司召开第八届董事会第四次会议审议通过了《关于控股股东向公司全资子公司提供借 款的议案》，表决结果：同意 9票，反对 0 票，弃权 0 票。 二、关联方介绍 翠微集团是海淀区国资委所属国有独资有限责任公司，法定代表人匡振兴，注册资本472.328.9994万 元，住所：北京市海淀区复兴路33 ...

Core Viewpoint - The company, Changchun High-tech Industry (Group) Co., Ltd., announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial application of the injectable GenSci136 drug, which is intended for the treatment of Immunoglobulin A Nephropathy (IgAN) [1][2]. Group 1: Drug Information - The product name is injectable GenSci136, and it is a Class 1 biological product developed by Jinsai Pharmaceutical for the treatment of IgAN [1]. - The clinical trial application was approved under acceptance number CXSL2600033, allowing the drug to proceed with clinical trials [1]. Group 2: Disease Context - IgAN is the most common primary glomerulonephritis globally and accounts for 39.73% of primary glomerulonephritis cases in China, primarily affecting individuals aged 30 to 40 [2]. - The disease progresses slowly but has a poor prognosis, with 20%-50% of patients eventually progressing to renal failure, posing a significant burden on families and the healthcare system [2]. - There is a substantial unmet clinical need for effective treatments for IgAN, as existing therapies have limitations in efficacy and safety [2]. Group 3: Drug Mechanism and Potential - Injectable GenSci136 is designed as a B-cell maturation antigen (BCMA) trimeric fusion protein, which enhances the blocking activity against endogenous ligands, potentially impacting the survival and differentiation of B lymphocytes and plasma cells [3]. - The drug aims to provide a new, safe, and effective first-line targeted treatment option for IgAN patients, with the potential for long-term application without the need for preventive anti-infection treatment [3].

Core Viewpoint - Beijing Zhongguancun Science and Technology Development (Holding) Co., Ltd. announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., has successfully passed the consistency evaluation for the generic drug Tramadol Hydrochloride Tablets (50mg) [1][2]. Group 1: Drug Approval Details - The drug name is Tramadol Hydrochloride Tablets, in tablet form, with a specification of 50mg [1]. - The approval notice number is 2026B00624, and the drug is classified as a chemical drug [1]. - The approval includes changes to the prescription, manufacturing process, production batch, quality standards, and shelf life [1]. Group 2: Market Context - The original drug has not been marketed in China, but there are currently eight generic versions approved, with three having passed the consistency evaluation [2]. - Beijing Huasu is the third domestic company to receive approval for this drug's consistency evaluation [2]. Group 3: Financial Investment - The total research and development investment for the consistency evaluation project of Tramadol Hydrochloride Tablets has reached approximately 5.9 million yuan [3]. Group 4: Impact on Company Performance - The approval is expected to enhance the market competitiveness of the drug and positively impact the company's operating performance [5]. - The company emphasizes the importance of drug research and development, maintaining strict quality control throughout the drug development, manufacturing, and sales processes [5].

证券代码：688617 证券简称：惠泰医疗 公告编号：2026-003 深圳惠泰医疗器械股份有限公司 第三届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 深圳惠泰医疗器械股份有限公司（以下简称"公司"）第三届董事会第三次会议通知于2026年2月9日发出 并送达全体董事，全体董事同意豁免本次会议的提前通知时限要求。本次会议于2026年2月9日以现场结 合通讯方式召开，会议应到董事9人，实到董事9人，出席董事占应出席人数的100%。本次会议的召 集、召开及表决程序符合《中华人民共和国公司法》等有关法律、行政法规、规范性文件和《深圳惠泰 医疗器械股份有限公司章程》的规定，会议决议合法有效。经与会董事审议和表决，会议形成决议如 下： 一、审议通过《关于以集中竞价交易方式回购股份方案的议案》 董事会认为，本次回购公司股份方案设计合理，有利于维护广大投资者利益，增强投资者对公司的投资 信心，建立健全公司长效激励机制，促进公司健康可持续发展，全体董事一致同意该事项。 具体内容详见公司同日在上海证券交易所网站（ ...

证券代码：603926 证券简称：铁流股份 公告编号：2026-004 铁流股份有限公司 关于预计日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要提示： ● 本次关联交易无需提交股东会审议。 （一）日常关联交易履行的审议程序 铁流股份有限公司（以下简称"公司"）于2026年2月9日召开了第六届董事会第十次会议，除关联董事张 智林、国宁回避表决，其余董事均审议通过了《关于预计日常关联交易的议案》。议案无需提交公司股 东会审议。 公司独立董事专门会议对上述日常关联交易事项进行了审议并全票通过该事项，认为公司本次预计日常 关联交易事项，均为公司正常生产经营中必要的、合理的行为，双方遵循公平、自愿、诚信的原则，交 易方式符合市场规则和公平原则，交易价格公允，符合公司的实际需要。关联交易不存在损害公司和非 关联股东利益的情形，也不会对公司独立性产生影响。 （二）前次日常关联交易的预计和执行情况 ■ 注：存款年度预计和实际发生金额为单日最高存款余额，在关联公司存款期末余额为0。 ● 公司与关联方之间的交易遵循了自愿 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002605 证券简称：姚记科技 公告编号：2026-008 债券代码：127104 债券简称：姚记转债 上海姚记科技股份有限公司 关于不提前赎回"姚记转债"的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大 遗漏。 特别提示： 1、上海姚记科技股份有限公司（以下简称"公司"）股票价格自2025年12月26日至2026年2月9日，已有 十五个交易日的收盘价不低于当期转股价格（即20.06元/股）的130%（即26.08元/股）。根据《上海姚 记科技股份有限公司向不特定对象发行可转换公司债券募集说明书》（以下简称"《募集说明书》"）的 约定，已触发"姚记转债"有条件赎回条款。 2、公司于2026年2月9日召开第六届董事会第二十五次会议，审议通过了《关于不提前赎回"姚记转 债"的议案》。公司董事会决定本次不行使"姚记转债"的提前赎回权利，且在未来三个月内（自2026年2 月10日至2026年5月9日）"姚记转债"再次触发有条件赎回条款时，公司均不行使提前赎回权利。自2026 年5月9日后首个交易日重新计算， ...

Group 1 - The company has approved a change in registered capital and amendments to its Articles of Association during the fourth meeting of the sixth board of directors held on February 9, 2026 [1] - The registered capital has increased from RMB 338,526,168 to RMB 346,507,013 following the issuance of 7,980,845 shares to specific investors [1] - The total number of shares has risen from 338,526,168 to 346,507,013 shares after the completion of share registration procedures [1] Group 2 - The amendments to the Articles of Association were made in accordance with relevant laws and regulations, reflecting the changes in registered capital [2] - Other provisions of the Articles of Association remain unchanged, and the revised document has been disclosed on the Shanghai Stock Exchange website [2] - The amendments were authorized by the shareholders at the annual general meeting held on March 20, 2025, and do not require further approval from the shareholders [2]

Core Viewpoint - The company has announced a change in the quality control reviewer for its 2025 annual audit, appointing Xu Juping in place of Wang Qichao due to internal adjustments at the auditing firm Zhonghui [1][4]. Group 1: Change in Quality Control Reviewer - The company held its 10th Board of Directors' ninth meeting on April 25, 2025, and the 2024 annual shareholders' meeting on June 5, 2025, where it approved the appointment of Zhonghui Certified Public Accountants as the auditing firm for the 2025 fiscal year [1]. - The original quality control reviewer Wang Qichao has been replaced by Xu Juping for the 2025 audit services due to internal adjustments at Zhonghui [1]. Group 2: Reviewer Background - The new quality control reviewer Xu Juping has no criminal penalties or administrative sanctions from regulatory bodies in the past three years [2]. - There are no circumstances that could affect the independence of the new quality control reviewer [3]. Group 3: Impact of Change - The transition of responsibilities during this change will be orderly, and it will not affect the financial statement audit and internal control audit for the 2025 fiscal year [4].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600971 证券简称：恒源煤电 公告编号：2026-012 安徽恒源煤电股份有限公司 关于以集中竞价交易方式回购公司股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份金额：不低于人民币20,000万元，不高于人民币25,000万元。 ● 回购股份资金来源：公司自有资金 ● 回购股份用途：回购股份用于转换公司发行的可转换公司债券。若公司未能在股份回购实施完成后三 年内转换完毕，未转换股份将依法履行相关程序后予以注销。 ● 回购股份价格：不超过人民币 9.55元/股。该价格不高于公司董事会通过回购股份决议前 30 个交易日 公司股票交易均价的 150%。 ● 回购股份方式：集中竞价交易方式 1.本次回购期限内，存在公司股票价格持续超出回购方案披露的价格上限，导致本次回购方案无法顺利 实施的风险； 2.若发生对公司股票交易价格产生重大影响的事项，或公司生产经营、财务状况、外部客观情况发生重 大变化，或其他导致公司董事会决定终 ...

Group 1 - The company held its 45th meeting of the 8th Board of Directors on February 9, 2026, via communication methods [3][5] - All 9 directors participated in the voting process, with unanimous approval for the resolutions [4][7] - The meeting was chaired by acting chairwoman Zhang Li, and senior management attended [5] Group 2 - The board approved the nomination of Ms. Li Xiaoguang as an independent director candidate, who meets the qualifications set by relevant regulations [6] - Upon approval by the shareholders' meeting, Ms. Li will also serve as the chair of the Compensation and Assessment Committee and a member of the Nomination Committee [6] - The independent director candidate's qualifications will be subject to review by the Shenzhen Stock Exchange before being submitted for shareholder approval [6] Group 3 - Ms. Li Xiaoguang has a distinguished background, including roles in arbitration and legal advisory, and has received multiple accolades for her contributions [10] - She does not hold any shares in the company and has no relationships with major shareholders or other board members [11] - Ms. Li's qualifications comply with the requirements of the Company Law and relevant regulations [11]